Navigation Links
A*STAR IHPC and IDA to Co-Develop Innovative Cloud-Enabled Technological Solutions for Local ICT Companies to be More Competitive
Date:9/4/2013

traditional IT structure[1]. The speed, reliability and feasibility of large scale data processing could be improved by dynamically optimising and scheduling the computational processes on cloud infrastructure such as Amazon EC2, S3, or Windows Azure. Such technologies in turn could be applied to a wide spectrum of areas such as aerospace, transport, surveillance, and healthcare.
  • Brand-Centric Social Media Analysis: IHPC scientists are working on a social media analyser to help customer-facing organisations to monitor, track and analyse near-to-real time social media perceptions about their businesses and identify emerging pertinent social media trends. It also allows fine tailoring of these tools and methods for specific organisations to achieve greater accuracy of results.
    • Complex Systems Modelling: IHPC scientists have won the top prize from the Institute of Electrical and Electronics Engineers (IEEE) in 2013 for scalable complex modelling, which involves using an analyser of multiple simulated scenarios to enable companies, for example, in the transport or logistic industries, to make faster decisions (such as significantly reducing turnaround time of 9 hours to 30 minutes) so as to achieve lower costs and enhance productivity.

    "The collaboration between IHPC and IDA will promote the use of cloud-based services and technologies, and enhance the productivity and competitiveness of local businesses. We envisage the availability of such resources will lower entry barriers of capital investment, and allow quicker idea-to-market implementation. IHPC will also offer its expertise in data analysis, computational modelling and simulation to ICT companies to strengthen innovation and deepen capabilities in developing solutions," said Professor Alfred Huan, Executive Director of IHPC.

    "This collaboratio
    '/>"/>

    SOURCE Agency for Science, Technology and Research (A*STAR)
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology technology :

    1. Pfizer, GSK, and Siemens Form R&D Consortium With A*STARs Institute of Chemical & Engineering Sciences
    2. Frost & Sullivan Recognizes A*STAR, Singapore with the 2012 Asia Pacific National Innovation Development Award
    3. PrimeraDx to Co-Develop Companion Diagnostics with Quest Diagnostics
    4. The Trendlines Group Announces Co-development Agreement with Endo
    5. Dr. David L. Blecker MD, MPH, F.A.C.P. Joins Inergetics Advisory Board to Co-Develop and Market Products to Penetrate Nephrology Market
    6. Cancer Patients to See More Precise Oncology Treatment via Innovative Life Sciences Coalition
    7. Chemists develop innovative nano-sensors for multiple proteins
    8. Newlight Named Most Innovative Company of the Year
    9. BIT Group to Showcase Innovative Hybrid System Design at AACC
    10. SoundConnect Launches Innovative Partner Incentive Program
    11. DuPont Tate & Lyle Bio Products Launches Innovative New Food Ingredient
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/22/2014)... Currently offering a comprehensive portfolio ... Weighing, Rice Lake, and Ohaus, Pipette.com has added ... Sartorius CPA Semi-Micro Balance is ideal for lab ... user-friendly laboratory balance. , Sartorius is a global ... balances are well known for their high performance, ...
    (Date:10/22/2014)... VANCOUVER , Oct. 22, 2014 /PRNewswire/ - iCo ... ICOTF), today announced next steps for its Oral ... findings from its in vitro work ... therapy.  iCo now plans to complete pre clinical ... an initial Phase 1A clinical trial, utilizing approximately ...
    (Date:10/20/2014)... 2014 Mapp Biopharmaceutical,s valiant effort to ... to fight the Ebola outbreak will make the ... production of pharmaceuticals can be, according to Kalorama ... while some may be taken aback by the ... industry knowledge are well aware of the complex ...
    (Date:10/20/2014)... GAITHERSBURG, Md. , Oct. 20, 2014  GenVec, Inc. ... Zola P. Horovitz , Ph.D., from its board of ... GenVec board in August 2003, and served as its chairman ... also served on the Nominating and Corporate Governance and Audit ... Zola for more than a decade of dedicated service to ...
    Breaking Biology Technology:Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Zola P. Horovitz To Retire From GenVec Board 2
    ... Vaccine Induced Neutralizing Antibodies and Protected Mice upon ChallengeROCKVILLE, ... NVAX ) announced results from a preclinical study of ... the viral fusion (F) protein. The virus utilizes ... respiratory tract and cause illness. Novavax,s RSV-F ...
    ... Boston Scientific Corporation (NYSE: BSX ) ... ended December 31, 2008. Subsequent to the release ... a patent litigation settlement and, as expected, finalized a ... U.S. Generally Accepted Accounting Principles, these events are required ...
    ... 26 InterMune, Inc.,(Nasdaq: ITMN ) today announced ... December 31, 2008. InterMune reported a net loss for ... share, compared with a,net loss of $25.9 million, or $0.67 ... Dan Welch, Chairman, Chief Executive Officer and ...
    Cached Biology Technology:NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus ('RSV') Vaccine Candidate Directed Against the Fusion (F) Protein 2NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus ('RSV') Vaccine Candidate Directed Against the Fusion (F) Protein 3NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus ('RSV') Vaccine Candidate Directed Against the Fusion (F) Protein 4Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge 2Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge 3Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge 4Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge 5Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge 6Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge 7Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge 8Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge 9Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge 10InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights 2InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights 3InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights 4InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights 5InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights 6InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights 7InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights 8InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights 9InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights 10InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights 11InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights 12
    (Date:10/16/2014)... human body. Battles are won, lost or sometimes ... stalemate—known as tumor dormancy—can last up to 25 ... is poorly understood. , A new computational ... a Professor of Chemistry at Princeton University, may ... the switch to a malignant state. Published today ...
    (Date:10/16/2014)... respiratory tract infections and worldwide claims the lives ... and Ghent University have succeeded in developing a ... infection. , Xavier Saelens (VIB/UGent): "We discovered ... for the development of a novel approach to ... in numerous small children and elderly people." , ...
    (Date:10/15/2014)... of Life, is a non-traditional biophysics textbook and it ... is a journey of discovery into biological systems and ... biological regulation. It is about how our genes make ... the billions of cells in an organism. It quantifies ... principles, which can be found on both large and ...
    Breaking Biology News(10 mins):Modeling tumor dormancy 2New perspectives for development of an RSV vaccine 2New book about life as seen from physics 2
    ... awarded a three-year grant from the U.S. Department ... economic impacts of the "biofuels revolution" on rural ... comes from the department,s Ethical, Legal and Societal ... Genomes or Nanotechnologies program. The researchers from K-State,s ...
    ... have a soft spot for Botswana, developed while reading ... have had a chance to do any sleuthing of ... when University of Illinois scientist Karen Chapman-Novakofski acquired a ... about the health and nutrition of that country,s elderly. ...
    ... at the University of Leeds have made a breakthrough ... greatest global disease threats to wild carnivores including lions, ... The discovery of how canine distemper Virus (CDV) jumps ... to a more effective monitoring and control of the ...
    Cached Biology News:K-State sociologists use Department of Energy grant 2U of I scientist does nutritional detective work in Botswana 2U of I scientist does nutritional detective work in Botswana 3Research sheds new light on how diseases jump across species 2
    Agarose, low melting/gelling temperature, high MW separation (>1000 bp), 25 g. Suitable for enzymatic modifications. Nuclease-free.Gel point: 24-30 C, EEO (-mr): 300 gm/cm2. Category: Nucleotides &...
    Request Info...
    Request Info...
    Epi-Grids™ Colony Grid Templates are easy-to-use griding templates that allow rapid organization of colonies from initial screening plates and for preparing precise master plates....
    Biology Products: